Cargando…

Factors That Determine the Prothrombin Time in Patients With Atrial Fibrillation Receiving Rivaroxaban

Rivaroxaban, a direct factor Xa inhibitor, is widely used to reduce the chance of stroke in patients with atrial fibrillation (AF). It is not clear why the prothrombin time (PT) of the international normalized ratio (INR) fails to correlate with treatment using rivaroxaban in patients with AF. In th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jen-Hung, Lin, Yung-Kuo, Chung, Cheng-Chih, Hsieh, Ming-Hsiung, Chiu, Wan-Chun, Chen, Yi-Jen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714846/ https://www.ncbi.nlm.nih.gov/pubmed/30244598 http://dx.doi.org/10.1177/1076029618800830

Ejemplares similares

Prothrombin Time-International Normalized Ratio Predicts the Outcome of Atrial Fibrillation Patients Taking Rivaroxaban
por: Chao, Tze-Fan, et al.
Publicado: (2022)

Rivaroxaban in atrial fibrillation
por: Giorgi, Mariano A, et al.
Publicado: (2012)

Therapeutic monitoring of rivaroxaban in dogs using thromboelastography and prothrombin time
por: Bae, Junwoo, et al.
Publicado: (2019)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Biological Variation in Rotational Thromboelastometry in Patients with Atrial Fibrillation Receiving Rivaroxaban
por: Božič Mijovski, Mojca, et al.
Publicado: (2022)

Real‐World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
por: Lin, Shin‐Yi, et al.
Publicado: (2019)

Rivaroxaban in atrial fibrillation cardioversion: an update
por: Lavalle, Carlo, et al.
Publicado: (2019)

Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J‐ROCKET AF Trials) in Asian Patients With Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2019)

Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
por: Chan, Yi-Hsin, et al.
Publicado: (2017)

Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling
por: Solms, Alexander, et al.
Publicado: (2019)

Initial rivaroxaban dosing in patients with atrial fibrillation
por: Ablefoni, Kaja, et al.
Publicado: (2019)

Rivaroxaban modulates electrical and mechanical characteristics of left atrium
por: Chang, Chien-Jung, et al.
Publicado: (2013)

Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

Vitamin D and bisphosphonates therapies for osteoporosis are associated with different risks of atrial fibrillation in women: A nationwide population-based analysis
por: Yang, Hung-Yu, et al.
Publicado: (2018)

Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation
por: Turpie, Alexander GG
Publicado: (2014)

Rhythm control without catheter ablation may have benefits beyond stroke prevention in rivaroxaban-treated non-permanent atrial fibrillation
por: Chiou, Wei-Ru, et al.
Publicado: (2022)

Left ventricular dysfunction in atrial fibrillation and heart failure risk
por: Kuo, Jen‐Yuan, et al.
Publicado: (2020)

Correction to: Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products
por: Castillo, Renee, et al.
Publicado: (2020)

Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands
por: Voss, Annemarie, et al.
Publicado: (2023)

Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021)

Four-factor prothrombin complex concentrate improves thrombin generation and prothrombin time in patients with bleeding complications related to rivaroxaban: a single-center pilot trial
por: Schenk, Bettina, et al.
Publicado: (2018)

Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation
por: Jacobs, Maartje S., et al.
Publicado: (2017)

Stroke prevention with rivaroxaban in higher‐risk populations with atrial fibrillation
por: Diener, H.‐C., et al.
Publicado: (2015)

Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients
por: Lai, Chao‐Lun, et al.
Publicado: (2017)

Hemorrhagic pericarditis associated with rivaroxaban in an atrial fibrillation patient with pacemaker
por: Rhew, Shi Hyun, et al.
Publicado: (2017)

Rivaroxaban-associated intracranial hemorrhage in Saudi atrial fibrillation patients
por: Alkhotani, Amal, et al.
Publicado: (2020)

Rivaroxaban-Associated Bullous Pemphigoid in a Patient With Atrial Fibrillation
por: Liang, Jiaming (Calvin), et al.
Publicado: (2021)

Activated Partial Thromboplastin Time or Prothrombin Time Prolongation During Rivaroxaban Administration: Clinical Risk Factors and Outcomes Analysis
por: Yuan, Yao, et al.
Publicado: (2023)

Author Correction: Rhythm control without catheter ablation may have benefits beyond stroke prevention in rivaroxaban-treated non-permanent atrial fibrillation
por: Chiou, Wei-Ru, et al.
Publicado: (2023)

Epicardial Adipose Tissue Thickness and Ablation Outcome of Atrial Fibrillation
por: Chao, Tze-Fan, et al.
Publicado: (2013)

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)
por: Beyer-Westendorf, Jan, et al.
Publicado: (2019)

Economic evaluation of rivaroxaban in stroke prevention for patients with atrial fibrillation in Greece
por: Kourlaba, Georgia, et al.
Publicado: (2014)

Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice
por: Vimalesvaran, Kavitha, et al.
Publicado: (2018)

Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018)

Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients
por: Konicki, Robyn, et al.
Publicado: (2020)

Comparison of Inflammatory Mediators in Patients With Atrial Fibrillation Using Warfarin or Rivaroxaban
por: Martins, Gabriela Lopes, et al.
Publicado: (2020)

Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
por: Alberts, Mark, et al.
Publicado: (2020)

Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
por: ASLAN, Onur, et al.
Publicado: (2022)

Insights on Distinct Left Atrial Remodeling Between Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction
por: Kuo, Jen-Yuan, et al.
Publicado: (2022)

Regional Diversities in Fibrogenesis Weighed as a Key Determinant for Atrial Arrhythmogenesis
por: Chung, Cheng-Chih, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9iqj1knlt8j5utd40e4qj3mp1m